Pilot Study of a GVAX Pancreas Vaccine (With Cyclophosphamide) in Combination With a PD-1 Blockade Antibody (Pembrolizumab) and a Macrophage Targeting Agent (CSF1R Inhibitor) for the Treatment of Patients With Borderline Resectable Adenocarcinoma of the Pancreas
Summary
The purpose of this pilot study is to look at whether combining cyclophosphamide, pembrolizumab (an antibody that blocks negative signals to T cells), GVAX (pancreatic cancer vaccine), and IMC-CS4 (LY3022855) (an antibody that blocks a molecule called CSF1-R which prevents the bodies ability to fight cancer) is effective (anti-tumor activity) and safe in patients with borderline resectable pancreatic cancer.
General Information
NCT#: NCT03153410
Study ID: J1766
Trial Phase: Pilot
Trial Sponsor: Eli Lilly, Merck Sharp & Dohme Corp., Sidney Kimmel Comprehensive Cancer Center
Therapies Used in This Trial: GVAX, Cyclophosphamide, Pembrolizumab, IMC-CS4